Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma

doi:10.1016/j.ajpath.2017.01.009

	Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma
	Hou, Shenda 1,2,3; Zhou, Shiyu 1,2,3; Qin, Zhen 1,2,3,4; Yang, Liu 1,2,3; Han, Xiangkun 1,2,3; Yao, Shun 1,2,3,4; Ji, Hongbin1,2,3,5
	2017-05
发表期刊	AMERICAN JOURNAL OF PATHOLOGY (IF:4.7[JCR-2023],4.8[5-Year])
ISSN	0002-9440
卷号	187 期号:5 页码:954-962
发表状态	已发表
DOI	10.1016/j.ajpath.2017.01.009
摘要	Lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC) are two distinct subtypes of non-small-cell lung carcinoma. Interestingly, approximately 4% to 9% of human non small-cell lung carcinoma tumors contain mixed adenomatous and squamous pathologies in a single lesion, clinically termed adenosquamous cell carcinoma. More important, these two different pathological components frequently share identical oncogenic mutations, indicative of a potential transition. Indeed, recent data have provided convincing evidence in supporting the ADC to SCC transdifferentiation in lungs. In the liver kinase B1 (official name STK11)-deficient mouse model, lung ADC can progressively trans differentiate to SCC through pathologically mixed adenosquamous cell carcinoma as the intermediate status. Mechanistic studies further identify essential roles of extracellular matrix remodeling and metabolic reprogramming during this phenotypic transition. Small molecular compounds, including lysyl oxidase inhibitors and reactive oxygen species-inducing reagents such as phenformin, significantly accelerate the transition from Lung ADC to SCC and thus confer lung tumors with drug resistance. Consistent with these findings, recent clinical studies have shown that epidermal growth factor receptor mutant lung ADC can transdifferentate to SCC in relapsed cancer patients. Together, these data support that this phenotypic transition from lung ADC to SCC might represent a novel mechanism for drug resistance. This review will summarize our current understanding of the transdifferentiation from lung ADC to SCC.
收录类别	SCI
语种	英语
资助项目	Science and Technology Commission of Shanghai Municipality grant[15XD1504000]
WOS研究方向	Pathology
WOS类目	Pathology
WOS记录号	WOS:000400229600002
出版者	ELSEVIER SCIENCE INC
WOS关键词	TYROSINE KINASE INHIBITORS ; YES-ASSOCIATED PROTEIN ; PEUTZ-JEGHERS-SYNDROME ; ADENOSQUAMOUS CARCINOMA ; LYSYL OXIDASE ; EXTRACELLULAR-MATRIX ; CANCER PROGRESSION ; POOR-PROGNOSIS ; HISTOLOGIC TRANSFORMATION ; IMMUNOHISTOCHEMICAL PANEL
原始文献类型	Review
引用统计	正在获取...
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/1396
专题	生命科学与技术学院_特聘教授组_季红斌组
通讯作者	Ji, Hongbin
作者单位	1.Chinese Acad Sci, Key Lab Syst Biol, Shanghai, Peoples R China 2.Chinese Acad Sci, Ctr Excellence Mol Cell Sci, Shanghai, Peoples R China 3.Chinese Acad Sci, Innovat Ctr Cell Signaling Network, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai, Peoples R China 4.Univ Chinese Acad Sci, Beijing, Peoples R China 5.Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China
通讯作者单位	生命科学与技术学院
推荐引用方式 GB/T 7714	Hou, Shenda,Zhou, Shiyu,Qin, Zhen,et al. Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma[J]. AMERICAN JOURNAL OF PATHOLOGY,2017,187(5):954-962.
APA	Hou, Shenda.,Zhou, Shiyu.,Qin, Zhen.,Yang, Liu.,Han, Xiangkun.,...&Ji, Hongbin.(2017).Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma.AMERICAN JOURNAL OF PATHOLOGY,187(5),954-962.
MLA	Hou, Shenda,et al."Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma".AMERICAN JOURNAL OF PATHOLOGY 187.5(2017):954-962.